Sera Prognostics, a women's health company, reported a net loss of $8.3 million for Q2 2024, an improvement from a $10.5 million net loss in Q2 2023. The company also saw a decrease in net loss for the first half of the year, reporting $16.4 million in 2024 compared to $21.1 million in 2023. Revenue for Q2 2024 was $24 thousand, down from $123 thousand in the same quarter the previous year. Operating expenses decreased, with research and development costs rising slightly due to increased bioinformatics activities. Sera Prognostics has focused on commercializing its PreTRM test, a blood-based biomarker test for predicting preterm birth risk, and is developing additional tests for other pregnancy conditions. The company has taken steps to reduce operating expenses and believes its cash runway is sufficient to operate...Show More

Sera Prognostics, a women's health company, reported a net loss of $8.3 million for Q2 2024, an improvement from a $10.5 million net loss in Q2 2023. The company also saw a decrease in net loss for the first half of the year, reporting $16.4 million in 2024 compared to $21.1 million in 2023. Revenue for Q2 2024 was $24 thousand, down from $123 thousand in the same quarter the previous year. Operating expenses decreased, with research and development costs rising slightly due to increased bioinformatics activities. Sera Prognostics has focused on commercializing its PreTRM test, a blood-based biomarker test for predicting preterm birth risk, and is developing additional tests for other pregnancy conditions. The company has taken steps to reduce operating expenses and believes its cash runway is sufficient to operate into 2027. Despite the net losses, Sera Prognostics has made significant strides in its business development, with its PRIME study showing efficacy and the AVERT PRETERM TRIAL demonstrating the benefits of the PreTRM test. Looking ahead, the company plans to expand market adoption of PreTRM and launch additional products, while also pursuing contracts with private and governmental payers to potentially generate material revenues.